Novo Nordisk’s weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly’s Zepbound, and now the company is trying to get back on track.

Activist hedge fund Parvus Asset Management is building a stake in Ozempic-maker Novo Nordisk as the drugmaker hunts for a ...

Coca-Cola remains resilient amid GLP-1 health trends and geopolitical risks, with proactive innovation and a diversified ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

Eli Lilly is a pharma player, but it offers the growth of a tech stock thanks to its weight loss drugs portfolio. The weight ...

Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Semaglutide Market Size, Share & Trends Analysis Report by Product (Ozempic ... healthcare infrastructure investments and increasing awareness ...

Investing.com -- The European Medicines Agency’s (EMA) safety committee, PRAC, said Friday that it has concluded that ...

(Reuters) -Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the competitive obesity drug market to ...

Ozempic-maker Novo Nordisk (NYSE:NVO) on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the competitive obesity drug market to ...